(HealthDay News) — Here are the latest clinical trials, courtesy of CenterWatch:

Diabetes (Pediatric)

This study seeks a variety of volunteers with type 1 diabetes for a study looking at environmental, immunologic, and genetic factors that may contribute to the disease’s onset. Candidates must be children under age six who have been diagnosed with diabetes within the last two weeks and adolescents ages 10-15 who have been diagnosed with diabetes within the last two weeks. This study requires a one-time visit to the Joslin Diabetes Center. Research site located in Boston, Mass.

More Information

Please see http://www.centerwatch.com/patient/studies/cat406.html.

—–

Crohn’s Disease

This study is evaluating the use of STA-5326 mesylate in patients with moderate-to-severe, active Crohn’s disease. Study visits include a screening visit, nine treatment visits over six months, and a follow-up visit that will occur 30 days following the end of treatment. Study drug treatment will continue for up to six months. Participants must be male or female ages 18 – 75 with Crohn’s disease diagnosed prior to screening. Research sites located throughout the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat51.html.

—–

Rectal Cancer

To determine if the addition student loan calculator of TNFerade to pre-operative chemoradiotherapy increases the number of pathologic complete responses when compared to pre-operative chemoradiotherapy alone as assessed following complete surgical resection of primary rectal cancer. Patients must be willing to return for follow-up, must be able to give and sign informed consent, must be suitable candidates for surgical resection post-chemoradiation, i.e. no history of sever congestive heart failure or severe pulmonary disease; and have a life expectancy greater than 16 months. Research site located in Bethesda, Md.

More Information

Please seo services see http://www.centerwatch.com/patient/studies/cat357.html.

—–

Copyright 2005 CenterWatch. All rights reserved.